Quote:Fox News Poll: Clinton leads Trump by 10 points
Source: Fox News
After the conventions, the Clinton-Kaine ticket leads the Trump-Pence ticket by 10 points (49-39 percent) in the race for the White House.
Clinton’s advantage is outside the poll’s margin of error. A month ago, Clinton was up by six points (44-38 percent, June 26-28).
Read more: http://www.foxnews.com/politics/2016/08/03/fo...lawed.html
Clinton 49
Trump 39
Panic approaches.
http://www.realclearpolitics.com/epolls/2016/...-5491.html
Sorry to post to Fox but they have the first post convention polls
FAUX News Poll no less. Ain't that a biatch? LOL! Fox
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Halozyme's Upcoming Investment Presentation at Healthcare Conference
Halozyme's Participation in Major Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) is set to showcase its advancements at an important healthcare conference. Dr. Helen Torley, the president and CEO, will present and engage in investor meetings, highlighting the company's innovative approaches in the biopharmaceutical sector. Details of the Presentation The...
Continue Reading
Emerging Markets Surge Ahead with Historic Bond Sales Strategy
Emerging Markets Adjust with Record Bond Sales Amid economic uncertainty, borrowers in developing regions are intensifying their efforts to navigate potential market turbulence, particularly due to significant fluctuations influenced by US economic conditions. Authorities and businesses have proactively begun securing funds through bond sales, reflecting a strategic move...
Continue Reading
Multi Ways Holdings Reflects on Fiscal Year 2024 Performance
Multi Ways Holdings Limited Reports on Financial Results Multi Ways Holdings Limited (NYSE American: MWG), a prominent provider of heavy construction equipment, has recently shared its financial outcomes for the fiscal year 2024. With a focus on innovation and customer satisfaction in Singapore and neighboring regions, the company continues to adapt to the dynamic market...
Continue Reading
Neurocrine Adjusts Course Following Luvadaxistat Study Setback
Neurocrine Biosciences Shifts Strategy After Luvadaxistat Trial Neurocrine Biosciences Inc. (NASDAQ: NBIX) has made revisions to its strategic approach following the outcomes of the ERUDITE phase two clinical trial involving luvadaxistat (NBI-1065844). This investigational treatment aimed at addressing cognitive impairment in schizophrenia did not achieve its primary...
Continue Reading
Rinnai America Leads Coalition Against DOE Water Heater Rule
Rinnai America Takes Action Against DOE Regulations Rinnai America Corporation, a prominent manufacturer of noncondensing tankless water heaters, has joined forces with 21 state attorneys general and various business groups to challenge the recent final rule issued by the U.S. Department of Energy (DOE) concerning consumer tankless water heaters. This action follows a...
Continue Reading